Home
World Journal of Advanced Research and Reviews
International Journal with High Impact Factor for fast publication of Research and Review articles

Main navigation

  • Home
    • Journal Information
    • Editorial Board Members
    • Reviewer Panel
    • Abstracting and Indexing
    • Journal Policies
    • Our CrossMark Policy
    • Publication Ethics
    • Issue in Progress
    • Current Issue
    • Past Issues
    • Instructions for Authors
    • Article processing fee
    • Track Manuscript Status
    • Get Publication Certificate
    • Join Editorial Board
    • Join Reviewer Panel
  • Contact us
  • Downloads

eISSN: 2581-9615 || CODEN: WJARAI || Impact Factor 8.2 ||  CrossRef DOI

Research and review articles are invited for publication in April 2026 (Volume 30, Issue 1) Submit manuscript

Convalescent plasma therapy for COVID-19

Breadcrumb

  • Home
  • Convalescent plasma therapy for COVID-19

Heena Bholaram Choudhary *, Rohan Rajkumar Patekar *, Akshita Pramod Jain, Pratiksha Davkare, Samkit Dilip Soni, Shreyans Pravin Chorbele and Sachin Devidas Rede

Department of Pharmaceutics, SJVPM Rasiklal M. Dhariwal Institute of Pharmaceutical Education and Research; Chinchwad, Pune-411019, MH- India.
 
Review Article
World Journal of Advanced Research and Reviews, 2021, 11(03), 192-200
Article DOI: 10.30574/wjarr.2021.11.3.0399
DOI url: https://doi.org/10.30574/wjarr.2021.11.3.0399
 
Received on 16 August 2021; revised on 18 September 2021; accepted on 20 September 2021
 
The outbreak of severe acute respiratory syndrome COVID-19 caused by SARS-CoV-2 in China represents a significant threat to global health. Unfortunately, effective therapeutic drugs and vaccines to cure SARS-CoV-2 are still lacking. Convalescent Plasma therapy which induces passive immunization seems a successful treatment for COVID-19 patients and also proves to be of huge value in terms of saving the severely ill patient. Plasma therapy acts by Blocking the Virus (Neutralization), Enhancing Phagocytosis (Opsonization), Immune System Activation (Complement Activation), and finally killing Virus (Antibody-Dependent Cell-mediated Cytotoxicity). Food and Drug Administration (FDA) of the United States was also given the stamp of approval for use of plasma therapy on 23 August 2020. In this review, we introduced the effective level of antibodies, potential mechanisms of CPT, WHO criteria for donating the plasma as well as future uncertainties of convalescent plasma therapy in the treatment of COVID-19 patients.
 
Convalescent plasma therapy; COVID-19; Neutralization; Passive immunization; Complement Activation
 
https://wjarr.com/sites/default/files/fulltext_pdf/WJARR-2021-0399.pdf

Preview Article PDF

Heena Bholaram Choudhary, Rohan Rajkumar Patekar, Akshita Pramod Jain, Pratiksha Davkare, Samkit Dilip Soni, Shreyans Pravin Chorbele and Sachin Devidas Rede. Convalescent plasma therapy for COVID-19. World Journal of Advanced Research and Reviews, 2021, 11(3), 192-200. Article DOI: https://doi.org/10.30574/wjarr.2021.11.3.0399

Copyright © Author(s). All rights reserved. This article is published under the terms of the Creative Commons Attribution 4.0 International License (CC BY 4.0), which permits use, sharing, adaptation, distribution, and reproduction in any medium or format, as long as appropriate credit is given to the original author(s) and source, a link to the license is provided, and any changes made are indicated.

All statements, opinions, and data contained in this publication are solely those of the individual author(s) and contributor(s). The journal, editors, reviewers, and publisher disclaim any responsibility or liability for the content, including accuracy, completeness, or any consequences arising from its use.

Get Certificates

Get Publication Certificate

Download LoA

Check Corssref DOI details

Issue details

Issue Cover Page

Editorial Board

Table of content

Copyright © 2026 World Journal of Advanced Research and Reviews - All rights reserved

Developed & Designed by VS Infosolution